![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 02, 2014 10:41:56 AM
Previous PR stated that they need more safety trials for HemaX which could take up to 4 months.
If Ichim and Koos have learned all that is needed for proper IND of dCellVax based on the HemaX IND difficulties, then I hope that yesterday's PR stating that they have all they need for dCellVax IND means it has the possibility of approval first time round, which means it will get priority over HemaX for first trial which is just fine with me. Should dCellVax help cure someone's cancer outright, we have high hopes of RGBP really gaining legs.
Agreed. We need HemaXellerate for the legitimacy it brings to instill confidence in serious investors. Assuming that it will reach clinical trials before dCellVax.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM